很抱歉，您的瀏覽器過於老舊無法閱讀網頁內容的需要，請更新瀏覽器或安裝 Google Chrome.

Investor Relations

FDA issues Study May Proceed letter for the PilotStudy of Pidnarulex Pharmacodynamics in patients withadvanced solid tumors, NCI-sponsored
FDA issues Study May Proceed letter for the PilotStudy of Pidnarulex Pharmacodynamics in patients withadvanced solid tumors, NCI-sponsored
Oct
14
2024
Senhwa Announces IND Submission to US FDA for thePilot Study of Pidnarulex Pharmacodynamics in Patientswith Advanced Solid Tumors sponsored by the US NCI
Senhwa Announces IND Submission to US FDA for thePilot Study of Pidnarulex Pharmacodynamics in Patientswith Advanced Solid Tumors sponsored by the US NCI
Sep
18
2024
US FDA Grants Rare Pediatric Disease Designation(PRDD) to Senhwa Biosciences Silmitasertib for PediatricNeuroblastoma
US FDA Grants Rare Pediatric Disease Designation(PRDD) to Senhwa Biosciences Silmitasertib for PediatricNeuroblastoma
Sep
13
2024
The Phase Ib expansion study abstract of CX-5461in solid tumor patients with BRCA2 and/or PALB2mutations is now on the ESMO 2024 website-Update URL
The Phase Ib expansion study abstract of CX-5461in solid tumor patients with BRCA2 and/or PALB2mutations is now on the ESMO 2024 website-Update URL
Sep
09
2024
Senhwa receives FDA Study May Proceed letter forthe PhaseI/II study of Silmitasertib in children andyoung adults with relapsed refractory solid tumors.
Senhwa receives FDA Study May Proceed letter forthe PhaseI/II study of Silmitasertib in children andyoung adults with relapsed refractory solid tumors.
Aug
06
2024
The abstract of Phase Ib expansion study ofCX-5461 in patients with solid tumors and BRCA2 and/orPALB2 mutation has been accepted at 2024 ESMO Congress
The abstract of Phase Ib expansion study ofCX-5461 in patients with solid tumors and BRCA2 and/orPALB2 mutation has been accepted at 2024 ESMO Congress
Jul
12
2024
Senhwa Biosciences Announces IND Submission to USFDA for the PhaseI/II study of Silmitasertib in children/dearyoung adults with relapsed refractory solid tumors.
Senhwa Biosciences Announces IND Submission to USFDA for the PhaseI/II study of Silmitasertib in children/dearyoung adults with relapsed refractory solid tumors.
Jul
11
2024
Senhwa announces the first patient dosed in thephase II study of CX-4945 with Community-AcquiredPneumonia associated with viral infection in Taiwan.
Senhwa announces the first patient dosed in thephase II study of CX-4945 with Community-AcquiredPneumonia associated with viral infection in Taiwan.
Mar
20
2024
Due to strategy adjustment, the Company decidesto early terminate the Phase II study of Silmitasertibto treat hospitalized patients with COVID-19.
Due to strategy adjustment, the Company decidesto early terminate the Phase II study of Silmitasertibto treat hospitalized patients with COVID-19.
Jan
05
2024
Yuanta Analyst Research Report of Senhwa Biosciences, Inc.
Yuanta Analyst Research Report of Senhwa Biosciences, Inc.

 Yuanta  Analyst Research Report of Senhwa Biosciences, Inc.

Dec
26
2019
Senhwa Biosciences Silmitasertib / Basal Cell Carcinoma Trial Completed 1st Patient Enrollment
Senhwa Biosciences Silmitasertib / Basal Cell Carcinoma Trial Completed 1st Patient Enrollment
Apr
17
2019
Senhwa Biosciences Silmitasertib filed IND of Medulloblastoma approved by FDA
Senhwa Biosciences Silmitasertib filed IND of Medulloblastoma approved by FDA
Jan
06
2019
The Company will be invited to present on a 2-days roadshow :「2018 Taiwan CEO Day」 in Singapore and Hong Kong on 25 and 26 August, 2018
The Company will be invited to present on a 2-days roadshow :「2018 Taiwan CEO Day」 in Singapore and Hong Kong on 25 and 26 August, 2018

1. Date: 08/25~26, 2018 2. Time: 09:00 3. Venue: Singapore/Hong Kong 4. Info: Presentation file as attached

Oct
22
2018
The Company will be invited by Yuanta Securities to present on 20 April, 2018
The Company will be invited by Yuanta Securities to present on 20 April, 2018

1. Date: 04/20, 2018 2. Time: 15:30 3. Venue: Taipei, Taiwan 4. Info: Presentation file as attached

Apr
18
2018
The Company will be invited to present on a 2-days roadshow :「2018 Taiwan CEO Day」 in Hong Kong from 12 April, 2018
The Company will be invited to present on a 2-days roadshow :「2018 Taiwan CEO Day」 in Hong Kong from 12 April, 2018

1. Date: 04/12~13, 2018 2. Time: 09:00 3. Venue: Hong Kong 4. Info: Presentation file as attached

Apr
09
2018
The Company will launch a two-day non-deal roadshow (NDR) in San Francisco USA from Jan 26 , 2018
The Company will launch a two-day non-deal roadshow (NDR) in San Francisco USA from Jan 26 , 2018

• The Company will launch a 2-day non-deal roadshow (NDR) in San Francisco starting from 26 Jan 2018, and the presentation file as attached.

Jan
25
2018
The Company will launch a three-day non-deal roadshow (NDR) in Singapore and Hong Kong starting from December 11 , 2017
The Company will launch a three-day non-deal roadshow (NDR) in Singapore and Hong Kong starting from December 11 , 2017

The Company will launch a three-day non-deal roadshow (NDR) in Singapore and Hong Kong starting from December 11 , 2017 and presentation files as attached.

Dec
08
2017

Back